Dudediligence.

Edgewise Therapeutics, Inc

EWTXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$34.1MSep ’24−$39.7MDec ’24−$40.8MMar ’25−$36.1MJun ’25−$40.7MSep ’25$117.4MDec ’25−$49.0MMar ’26−$57.3MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating income−$43.2M−$71.7M−$114.4M−$158.8M−$191.4M
Net income−$42.8M−$67.6M−$100.2M−$133.8M−$167,795
Operating cash flow−$33.5M−$52.6M−$91.9M−$109.0M−$143.8M
Free cash flow−$34.2M−$58.2M−$97.7M−$110.3M−$144.1M
Cash$15.6M$22.0M$86.1M$41.7M$61.1M
Shares outstanding49.5M63.3M70.5M94.8M106.2M